Abstract
Background COVID-19 poses a major challenge to infection control in care homes. SARS-CoV-2 is readily transmitted between people in close contact and causes disproportionately severe disease in older people.
Methods Data and SARS-CoV-2 samples were collected from patients in the East of England (EoE) between 26th February and 10th May 2020. Care home residents were identified using address search terms and Care Quality Commission registration information. Samples were sequenced at the University of Cambridge or the Wellcome Sanger Institute and viral clusters defined based on genomic and time differences between cases.
Findings 7,406 SARS-CoV-2 positive samples from 6,600 patients were identified, of which 1,167 (18.2%) were residents from 337 care homes. 30/71 (42.3%) care home residents tested at Cambridge University Hospitals NHS Foundation Trust (CUH) died. Genomes were available for 700/1,167 (60%) residents from 292 care homes, and 409 distinct viral clusters were defined. We identified several probable transmissions between care home residents and healthcare workers (HCW).
Interpretation Care home residents had a significant burden of COVID-19 infections and high mortality. Larger viral clusters were consistent with within-care home transmission, while multiple clusters per care home suggested independent acquisitions.
Funding This work was funded by COG-UK (supported by the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute); the Wellcome Trust; the Academy of Medical Sciences; the Health Foundation; and the Cambridge NIHR Biomedical Research Centre.
Evidence before this study Previous epidemiological studies of COVID-19 in care homes have been limited in population size, temporal scale and/or the amount of genomic data included. One study in a skilled nursing facility in Washington State, USA, found that 57/89 (64%) residents were SARS-CoV-2 positive and that 27/34 (79%) had genetically similar viral sequences. Another study in four nursing homes in London, UK, found that 126/313 (40%) of residents were SARS-CoV-2 positive; sequencing of 19 samples identified clusters within care homes. Screening and sequencing of staff at five long-term care facilities in Colorado, USA over a two-week period identified a number of clusters among staff working at the same facility, but did not include sequences from residents. A single sequence reported from a care home resident in Hungary was found to differ from other Hungarian SARS-CoV-2 sequences. Finally, an epidemiological study of COVID-19 in 189 care homes in Scotland did not include any genomic data.
Added value of this study This study includes care home residents tested during the course of the first phase of the COVID-19 pandemic in a large geographical region in the UK. It is more comprehensive and representative than previous studies and includes detailed metadata and genomic data, which are being made openly available as a resource for other researchers. We used a clustering algorithm and demonstrated how genomic and epidemiological data can be integrated to define possible transmission networks.
Implications of all the available evidence Detailed combined epidemiological and genomic studies are essential to improve our understanding of the transmission and impact of SARS-CoV-2 in long term nursing and residential facilities. Our study has identified two patterns of transmission (outbreaks within care homes and multiple, distinct clusters among care home residents from the same care homes) that will require tailored infection control measures to prevent and mitigate them.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by COG-UK (supported by the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute); the Wellcome Trust; the Academy of Medical Sciences; the Health Foundation; and the Cambridge NIHR Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted as part of surveillance for COVID-19 infections under the auspices of Section 251 of the NHS Act 2006. It therefore did not require individual patient consent or ethical approval. The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The genome sequence data are available through the COVID-19 Genomics Consortium UK and the MRC-CLIMB websites.
